A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Michael Sun,Jones T. Nauseef,Justin M Lebenthal,Muhammad Junaid Niaz,Sharon Singh,Tessa A Chamberlain,Mahelia Bissassar,Amie Patel,Angela Tan,Shankar Vallabhajosula,John W. Babich,Paul J. Christos,Joseph R. Osborne,Ana M. Molina,Cora N. Sternberg,David M. Nanus,Neil H. Bander,Scott T. Tagawa

A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

2021

Michael Sun
Jones T. Nauseef
Justin M Lebenthal
Muhammad Junaid Niaz
Sharon Singh
Tessa A Chamberlain
Mahelia Bissassar
Amie Patel
Angela Tan
Shankar Vallabhajosula
John W. Babich
Paul J. Christos
Joseph R. Osborne
Ana M. Molina
Cora N. Sternberg
David M. Nanus
Neil H. Bander
Scott T. Tagawa

TPS188Background: Prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT) is a promising treatment. PSMA-targeting via large antibodies vs small molecules has different ...

Keywords:

dose escalation
Prostate cancer
Cancer research
phase i ii
castration resistant
multiple dose
Antibody
membrane antigen
Medicine
Targeted radionuclide therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations